中国医科大学学报2012，Vol.41Issue(4)：373-376,4.
美罗华联合CHOP方案与单用CHOP方案治疗Ⅲ、Ⅳ期弥漫大B细胞性淋巴瘤的临床对比研究
Comparison of Efficacy and Safety between Rituximab plus CHOP and CHOP Regimen on Patients with Stage Ⅲ and Ⅳ Diffuse Large B-cell Lymphoma
王晓雪 1高然 1于锦香 1蔡大利 1李艳1
作者信息
- 1. 中国医科大学附属第一医院血液科,沈阳110001
- 折叠
摘要
Abstract
Objective To compare the effect and safety of rituximab plus CHOP (R-CHOP) and CHOP regimen on patients with stage III and IV diffuse large B-cell lymphoma (DLBCL). Methods A total of 56 patients with Stage III and IV DLBCL were non-randomly divided into two groups:26 patients were treated with R-CHOP,the others with CHOP. NHL international efficacy assessment and WHO criteria were used to assess the therapeutic and the adverse effects respectively. Results The overall response rate of R-CHOP group was 88.5%, including 15 complete remissions (CR) and 8 partial remissions (PR),and that of the CHOP group was 63.3% with 11 CR and 8 PR. The response rate was significantly higher in R-CHOP group than that in CHOP group (F =0.036). The one-year survival rate was 96.1% in R-CHOP group and 76.7% in CHOP group,respectively. The one-year progression-free survival (PFS) rates were 80.8% and 56.7%,respectively. There were significant differences between one-year survival rates and PFS rates in two groups (P < 0.05). The major side effects in both regimens were gastrointestinal toxicity.mild to moderate myelosuppression,and adverse reactions to transfusion with no significant difference (P> 0.05). Conclusion Compared with CHOP,R-CHOP regimen increases the therapeutic efficacy in patients with stage I and IV DLBCL,and has no significant increase in toxicity. R-CHOP regimen should be applied to the fust line chemotherapy.关键词
弥漫大B细胞淋巴瘤/美罗华/化疗/CHOP方案Key words
difluse large B-cell lymphoma/ rituximab/ chemotherapy/ CHOP regimen分类
医药卫生引用本文复制引用
王晓雪,高然,于锦香,蔡大利,李艳..美罗华联合CHOP方案与单用CHOP方案治疗Ⅲ、Ⅳ期弥漫大B细胞性淋巴瘤的临床对比研究[J].中国医科大学学报,2012,41(4):373-376,4.
